Timing is everything in dealmaking.
Novartis’ plan to acquire RNA medicines company Avidity Biosciences for $12 billion was already the second-biggest biotech buyout of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
